TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent that alters reactive oxygen species tumor m...

Descripción completa

Detalles Bibliográficos
Autores principales: Anders, Carey, Deal, Allison M., Abramson, Vandana, Liu, Minetta C., Storniolo, Anna M., Carpenter, John T., Puhalla, Shannon, Nanda, Rita, Melhem-Bertrandt, Amal, Lin, Nancy U., Kelly Marcom, P., Van Poznak, Catherine, Stearns, Vered, Melisko, Michelle, Smith, J. Keith, Karginova, Olga, Parker, Joel, Berg, Jonathan, Winer, Eric P., Peterman, Amy, Prat, Aleix, Perou, Charles M., Wolff, Antonio C., Carey, Lisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112043/
https://www.ncbi.nlm.nih.gov/pubmed/25001612
http://dx.doi.org/10.1007/s10549-014-3039-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112043/
https://www.ncbi.nlm.nih.gov/pubmed/25001612
http://dx.doi.org/10.1007/s10549-014-3039-y

Ejemplares similares